Trial reportEuropean journal of nutrition2026
Does inflammation moderate the effect of vitamin D supplementation on depressive symptoms? Results of an interventional study in children and adolescents.
Trial report in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStudies in adults suggest antidepressant effects of vitamin D, possibly via anti-inflammatory pathways, but evidence in youth is lacking. In the first randomized controlled trial (RCT) in depressed, vitamin D-deficient adolescents (DRKS00009758), symptom reduction emerged in only one of three outcomes. This secondary analysis investigates whether baseline inflammatory status modifies the effect of vitamin D.
methodsData from 92 participants (78.3% ♀) of the RCT conducted at the Department of Child and Adolescent Psychiatry were analyzed. All participants were deficient in vitamin D [25(OH)D ≤ 30 nmol/l] and at least mild depressive symptoms [Beck Depression Inventory-II (BDI-II) ≥ 14]. Participants received 2640 IU/day of vitamin D or placebo for 28 days plus treatment as usual. Depressive symptoms were assessed via BDI-II and the Diagnostic System for Mental Disorders in Childhood and Adolescence (DISYPS), self- and proxy-rated. C-reactive protein (CRP) was measured at baseline as an inflammatory marker. Its impact on treatment effects was examined via interaction analyses and stratification by CRP status.
resultsIn 81.5% of the participants, CRP levels were below the threshold for low-grade inflammation (3 mg/L). No consistent interaction between treatment and baseline CRP was observed across outcomes. A nominal interaction for self-rated DISYPS at the 3 mg/L threshold lost significance after correction for multiple testing. Stratified analyses using different CRP thresholds revealed no significant subgroup effects.
conclusionsOverall, our findings do not support the hypothesis that the antidepressant effects of vitamin D supplementation in children and adolescents depend on baseline CRP status—at least within a sample characterized by minimal baseline inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.